A Message from Stocks.News 
European Cannabis is Attractive to Smart Money Investors and This Little-Known Company is Leading the Way in Premium Cannabis Cultivation and Distribution. $200m in strategic investments have been made into early-stage European cannabis companies recently. The market is flourishing, and one little-known company is leading the way in production on the continent. This company is building a seed-to-patient supply chain, connecting patients in the UK and Europe with diverse products including cannabis products cultivated at its grow operations in Portugal and with other trusted third-party brands. The company is now established as Europe’s premium cannabis cultivator! Committed to the highest quality standards under EU GACP, the company is utilizing proven genetics from world-class partners and building its own leading library. Market access is impressive with multiple routes to market with large distributors in Germany and respected telehealth partners in the UK. Since legalizing medical cannabis in 2018, Portugal has become a global hub for medical cannabis production. This company’s portfolio includes Holigen, a Portugal-based cultivator, manufacturer, and distributor with a prized EU GMP-certified premium indoor grow facility. The company’s presence in the German medical cannabis market today is also building brand awareness ahead of adult-use legalization, expected by 2024. The company is also making significant strides in advancing the global medical cannabis industry with the recent signing of a definitive Share Purchase Agreement and Escrow Agreement with Somai Pharmaceuticals Unipessoal, LDA. This strategic move underlines the company’s commitment to enhancing patient access to high-quality cannabis treatments. Learn how this company is leading the cannabis revolution and pioneering global access to premium cannabis treatments! | 
No comments:
Post a Comment